Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD

Bernardo Moreira Soares Oliveira1, Madeleine Durbeej1, Johan Holmberg1

  • 1Muscle Biology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.

Plos One
|August 4, 2017
PubMed

Insights

MicroRNA-21 (miR-21) does not appear to drive fibrosis in laminin-deficient congenital muscular dystrophy (LAMA2-CMD). Eliminating miR-21 in mouse models did not improve muscle fibrosis or disease symptoms.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression.
  • Fibrosis is a major pathological feature in laminin-deficient congenital muscular dystrophy (LAMA2-CMD).
  • Previous studies indicated a potential role for miR-21 in promoting fibrosis in LAMA2-CMD.

Purpose of the Study:

  • To investigate the role of miR-21 in the development of fibrosis in LAMA2-CMD.
  • To determine if the absence of miR-21 could ameliorate the disease phenotype in LAMA2-CMD mouse models.

Main Methods:

  • Generated double knockout mice by crossing LAMA2-CMD mouse models (dy3K/dy3K and dy2J/dy2J) with miR-21 knockout mice.
  • Assessed muscle fibrosis, body weight, and muscle function in the resulting double knockout mice (dy3K/miR-21 and dy2J/miR-21) compared to their respective LAMA2-CMD counterparts.

Main Results:

  • Absence of miR-21 did not improve the muscular dystrophy phenotype in LAMA2-CMD mice.
  • Double knockout mice exhibited similar body weight, muscle fibrosis, and impaired muscle function compared to LAMA2-CMD mice without miR-21 deficiency.
  • These findings suggest miR-21 is not involved in LAMA2-CMD fibrosis development.

Conclusions:

  • miR-21 does not appear to play a significant role in the pathogenesis of fibrosis in LAMA2-CMD.
  • Targeting miR-21 may not be an effective therapeutic strategy for LAMA2-CMD-associated fibrosis.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
6.2K